Cardiovascular diseases remain a major challenge for modern drug discovery. The diseases are chronic, complex, and the result of sophisticated interactions between genetics and environment involving multiple cell types and a host of systemic factors. The clinical events are often abrupt, and the diseases may be asymptomatic until a highly morbid event.
arrhythmias ranging from simple atrial premature beats to malignant ventricular tachycardia are remarkably similar, as a consequence of the lack of definitive mechanistic insight into many clinical arrhythmias. The resultant targeting of "final common pathways" or even normal physiology with blunt pharmacological tools rather than the precise manipulation of disease-specific mechanisms leads to predictable problems (6) (7) (8) . Not surprisingly, many effective antiarrhythmic agents are also highly proarrhythmic in particular contexts, and these "ontarget" adverse effects have become all too apparent, with several costly failures in large randomized clinical trials (3, 9, 10) . In this paper, we outline evidence that most existing cardiovascular drug targets are poorly validated, review emerging data on the role of mechanistic insight in drug discovery for specific cardiovascular diseases in humans, and discuss recent advances using direct in vivo chemical screens in zebrafish for the discovery of novel cardiovascular tool compounds and drug leads.
CHOOSING CARDIOVASCULAR TARGETS
Chronic cardiovascular diseases pose several fundamental problems for drug development (1, 11) . Clinical events may present abruptly and often with severe consequences (arterial occlusion, paroxysmal arrhythmia, venous thrombosis, or complex vasomotor syncopal events), but the underlying myocardial, vascular, or systemic substrate may be totally undetectable by conventional technologies (12) (13) (14) (15) (16) .
Indeed, the investigation of many chronic cardiovascular disorders is characterized by difficulty in making a negative diagnosis. This dilemma has driven cardiovascular medicine to exploit the concept of risk factors, treating higher risk cohorts identified by specific downstream biomarkers but without overt manifestations of disease, to enable the prevention of disorders (17) .
Arrhythmias are an excellent paradigm for much of common complex cardiovascular disease because they are often paroxysmal, limiting the utility of direct approaches to detection and confounding rigorous evaluation of pharmacological or other therapeutic interventions. For many clinically significant arrhythmic syndromes, lifetime risk that an episode will occur may be quite low, but the risk from each individual paroxysm for a morbid or mortal outcome may be quite high (18) . Similarly, for arterial occlusive events, even the presence of existing partially obstructive lesions is not a particularly effective predictor of subsequent acute events (19) . In addition, the lack of accessibility of cardiac and vascular tissue has At the core of these concepts is an implied need to carefully balance the risks of a specific condition and the risks of any new therapeutics throughout the development process. These concepts have been framed under the rubric of precision or individualized medicine, which recently has become the focus of major federal initiatives (21, 22) . Real individualization of medicine dictates remarkable changes in almost everything that we do. It will require a new wave of studies to define the etiologic basis of each disease subset, mechanism-specific diagnostics, transformative approaches to disease modeling, and drug discovery on a previously unimagined scale (23) .
Although this is well under way for clonal neoplasia, it will not be feasible in the management of chronic cardiovascular diseases until we have robust approaches to the identification of fundamental mechanisms; detection of subclinical disease; costeffective, efficient, and predictive disease models;
and truly scalable approaches to drug discovery in mechanistically faithful models (22) (23) (24) .
BEYOND TRADITIONAL TARGETS
To date, cardiovascular discovery has focused on a limited repertoire of molecular targets. In myocardial disease, almost every successful agent has transferred from the antihypertensive field, even in situations in which there are intrinsic cellular myocardial abnormalities such as hypertrophic cardiomyopathy (20, 25, 26) . In arrhythmias, almost all of the activities in drug discovery have been focused on transmembrane ion fluxes and the associated channels or
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ion exchangers required to generate these (27 (28, 30) . Similarly, ion channel gene mutations are known to be the major causes of rare inherited arrhythmias, including the long-QT and Brugada syndromes (14) , and drove extensive programs designed to identify specific inhibitors of individual ion channels or currents, on the premise that through modulating basic ion channel physiology it would be possible to adjust arrhythmic risk in a beneficial direction (32) . Despite this investment, such ion channel-focused discovery has, to date, largely failed to diminish mortality or morbidity from arrhythmias.
These challenges across multiple fields appear to be the result of several conceptual hurdles, which the drug discovery process itself has uncovered (29, 30) .
For example, the initial assumption that arrhythmias are a direct consequence of abnormalities of passive conductance alone has not borne deeper scrutiny.
Definitive genetic manipulations of channel density or net ionic flux have rarely lead to spontaneous arrhythmias, though in truth these experiments are complicated to interpret given the idiosyncrasies of murine cardiac electrophysiology (33) . Powerful homeostatic effects counter major effects from null alleles in major ion channel genes. However, targeted knock-in in these same genes of alleles that cause human disease does result in spontaneous arrhythmias (34) . These data suggest that arrhythmias result from very specific "gain of function" effects in ion channels rather than simple modulation of ion conductance.
Similarly, the knowledge that heart failure is caused by Unrevealed signaling roles of the various ion channels likely underlie the lack of efficacy seen with simple conductance modulation, while also explaining some of the proarrhythmia observed with such agents (2, 27) . Toxic effects may also result from "on-target" activity against extracardiac isoforms (e.g., neuronal
or smooth muscle) (36) .
Careful study of cardiovascular disease in all of its forms also implies that manipulation of single mole- 
COMPLEX SYSTEMS
As genetic and genomic studies flesh out the picture of disease pathophysiology, so the remarkable
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DRUG DISCOVERY IN THE FACE OF IRREDUCIBLE COMPLEXITY
Drug discovery has traditionally involved the isolation of a specific target molecule, the design of a robust and scalable assay for this single target's activity, and the completion of an empirical screen of large chemical libraries for entities with the desired effect in this refined assay (29, 30) . Clearly, the choice of target is a major decision node in this process and is often the source of subsequent problems. Target choice is often based on a host of factors that may have little to do with the disease biology in humans, such as prior work in the area, perceived
C C : B A S I C T O T R A N S L A T I O N A L S C I E N C E V O L . 2 , N O . 1 , 2 0 1 7
Kithcart and MacRae To optimize sensitivity, specificity, and throughput, an initial high-throughput screen for abnormal heart rate response to dofetilide was combined with a second high-resolution assay in which confirmed mutants are studied using optical mapping. Subsequent testing in the absence of dofetilide allowed discrimination between pure drug response phenotypes and intrinsic heart rate defects. In the initial shelf screen
Zebrafish Discovery Screens The core concept of the phenotypic screen is illustrated. Using a genetically modified fish, it is possible to recapitulate much, if not all, of the fundamental biology of the disease as well as the molecular and cellular homeostatic responses to the primary defect. Because zebrafish offspring can survive in multiwell plates, if high-throughput phenotypes can be developed that represent the disease endpoints, a chemical suppressor screen can be undertaken to identify tool compounds or drug leads. Such screens have been successfully undertaken to prioritize hundreds or lead compounds or to screen in an unbiased manner hundreds of thousands of small molecules. Importantly, toxicity can also be addressed in parallel during the same screens.
Zebrafish Discovery Screens initiation, it is feasible to mitigate any confounders in the overall design. Pre-specified replication steps can be introduced or individual assays can be combined in series to optimize the sensitivity and specificity of the overall screen. In this construct, an investigator can create a staged series of assays with initial highthroughput and high-sensitivity assays paired with subsequent lower throughput but more stringent high-specificity follow-up assays designed to create an integrated final output with the desired characteristics. These principles are beginning to be applied in a variety of different drug discovery screens for discrete cardiovascular endpoints, with the goal of accelerating the pace of translation to the clinic.
RECENT SCREENS FOR CARDIOVASCULAR COMPOUNDS IN THE ZEBRAFISH
The utility of unbiased in vivo screens in cardiovascular disease is now beginning to be realized in different disease models including arrhythmias, heart failure, and cardiotoxicity. Kithcart and MacRae
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